Vaxcyte (FRA:5VA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:5VA Vaxcyte Inc FRA:5VA
35 GF Score
Price €45.40
! 2 Warning Signs
View Full Analysis

What is Vaxcyte Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vaxcyte's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:5VA vs CORT, IBRX, HALO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vaxcyte's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxcyte Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vaxcyte's Margin of Safety % (DCF Earnings Based) falls into.


FRA:5VA
35GF Score
Vaxcyte Inc FRA:5VA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxcyte Business Description

Other Exchanges PCVX:USA1PCVX:Italy
Address 825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
35GF Score

Get the complete analysis for FRA:5VA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.40
Price